A Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside?

Abstract

Metastatic castration-resistant prostate cancer (mCRPC) is a natural sequela in advanced prostate cancer following resistance to standard treatment regimes, where patients develop with rising PSA, bone pains, and high disease volume. Further palliative treatment is the need of the hour for ensuring disease control and quality of life. In recent times, many novel methods have been evolved for these patients. Endo-radioligand therapy with Lutetium 177 prostate-specific membrane antigen 617 (Lu-177 PSMA) based on the Theranostic concept has emerged as a promising tool among these. We present here the current status of Lu177-PSMA for mCRPC patient and future directions.

Keywords:

• Metastatic castration-resistant prostate cancer
• Lu-177 PSMA
• Bench to bedside
• Theranostic
• Radioligand therapy

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.